AQR Capital Management LLC Has $728.72 Million Stock Holdings in Johnson & Johnson $JNJ

AQR Capital Management LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 8.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,795,489 shares of the company’s stock after selling 470,221 shares during the period. Johnson & Johnson makes up approximately 0.6% of AQR Capital Management LLC’s portfolio, making the stock its 13th biggest position. AQR Capital Management LLC owned approximately 0.20% of Johnson & Johnson worth $728,723,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Clark Asset Management LLC grew its stake in shares of Johnson & Johnson by 51.6% in the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after acquiring an additional 3,025 shares in the last quarter. Apexium Financial LP boosted its position in Johnson & Johnson by 10.7% in the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after purchasing an additional 2,310 shares during the last quarter. Avanza Fonder AB boosted its position in Johnson & Johnson by 2.9% in the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after purchasing an additional 6,566 shares during the last quarter. Winnow Wealth LLC bought a new position in Johnson & Johnson during the second quarter valued at about $295,000. Finally, 111 Capital increased its holdings in Johnson & Johnson by 94.0% during the second quarter. 111 Capital now owns 12,474 shares of the company’s stock worth $1,905,000 after buying an additional 6,045 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on JNJ shares. HSBC reiterated a “buy” rating and issued a $240.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Guggenheim upped their price target on shares of Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Raymond James Financial lifted their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Barclays increased their target price on Johnson & Johnson from $176.00 to $197.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Finally, Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target for the company in a research report on Monday, October 20th. Four analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $206.65.

Johnson & Johnson Trading Up 0.8%

Shares of JNJ opened at $211.65 on Friday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $212.27. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a market capitalization of $509.93 billion, a P/E ratio of 20.43, a P/E/G ratio of 2.34 and a beta of 0.36. The firm’s 50 day simple moving average is $196.09 and its 200 day simple moving average is $177.08.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion for the quarter. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.